Enterprise Value
166.7M
Cash
88.89M
Avg Qtr Burn
-7.959M
Short % of Float
0.22%
Insider Ownership
0.00%
Institutional Own.
0.62%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LUMOXITI Details Hairy Cell Leukemia | Approved Quarterly sales | |
Monalizumab + durvalumab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 3 Update | |
Monalizumab (anti-NKG2A) Details Solid tumor/s, Cancer | Phase 2 Data readout | |
Avdoralimab (IPH5401) Details COVID-19 | Phase 2 Data readout | |
Lacutamab (IPH4102) Details Lymphoma, Cancer, Mycosis fungoides | Phase 2 Data readout | |
Lacutamab (IPH4102) Details Cancer, Lymphoma, Peripheral T cell cancer | Phase 2 Data readout | |
Lacutamab (IPH4102) Details Lymphoma, Sezary syndrome, Cancer | Phase 2 Data readout | |
IPH5201 Details Cancer, Lung cancer | Phase 2 Initiation | |
IPH6401 / SAR’514 Details Cancer, relapsed or refractory light chain amyloidosis, Multiple myeloma | Phase 1/2 Data readout | |
IPH6101/SAR’579 Details Cancer, B-cell acute lymphoblastic leukemia, Relapsed/refractory acute myeloid leukemia | Phase 1/2 Update | |
IPH5301 (anti-CD73) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
Monalizumab (anti-NKG2A) Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer | Failed Discontinued | |
Avdoralimab (IPH5401) Details Bullous pemphigoid , Skin disease/disorder | Failed Discontinued |